Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 14/20 | 0.43 |
| ▸ | NPY1R | P25929 | 8/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.43 |
| ▸ | NPY2R | P49146 | 5/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 2/20 | 0.38 |
| ▸ | FNTB | P49356 | 2/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30695170 | 0.94 | PTGS1 (0.43) | NPY4RNPY1RNPY5RNPY2RPTGS1 | |
| SCHEMBL30887063 | 0.92 | PTGS1 (0.43) | NPY4RNPY1RNPY5RNPY2RPTGS1 | |
| SCHEMBL14518642 | 0.91 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RPTGS1 | |
| SCHEMBL29568701 | 0.91 | PTGS1 (0.43) | NPY4RNPY1RNPY5RNPY2RPTGS1 | |
| SCHEMBL30767724 | 0.91 | PTGS1 (0.43) | NPY4RNPY1RNPY5RNPY2RPTGS1 | |
| SCHEMBL30509913 | 0.91 | PTGS1 (0.43) | NPY4RNPY1RNPY5RNPY2RPTGS1 | |
| SCHEMBL30509912 | 0.91 | PTGS1 (0.43) | NPY4RNPY1RNPY5RNPY2RPTGS1 | |
| SCHEMBL29647783 | 0.89 | PTGS1 (0.40) | NPY4RNPY1RNPY5RNPY2RPTGS1 | |
| SCHEMBL30753507 | 0.89 | PTGS1 (0.40) | NPY4RNPY1RNPY5RNPY2RPTGS1 | |
| SCHEMBL25639021 | 0.89 | PTGS1 (0.40) | NPY4RNPY1RNPY5RNPY2RPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312495-A1 | ORGANOMETALLIC GOLD(III) COMPLEXES FOR RADIOLABELING BIOMOLECULES FOR APPLICATIONS IN POSITRON EMISSION TOMOGRAPHY (PET) MOLECULAR IMAGING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312495-A1 | ORGANOMETALLIC GOLD(III) COMPLEXES FOR RADIOLABELING BIOMOLECULES FOR APPLICATIONS IN POSITRON EMISSION TOMOGRAPHY (PET) MOLECULAR IMAGING | SSTR3, NEU3, IGFBP3 | NPY4R 926/4885NPY1R 869/4885NPY5R 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.